FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022072056> ?p ?o ?g. }

• W2022072056 endingPage "198" @default.
• W2022072056 startingPage "191" @default.
• W2022072056 abstract "WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Conventional spacers help overcome problems with co‐ordination and may improve lung deposition and decrease oropharyngeal impaction. • Antistatic spacers eliminate electrostatic charge and may hence improve respirable dose delivery. • The systemic bioavailability of inhaled fluticasone propionate is primarily dependent on delivery by the pulmonary route and hence the performance of antistatic spacers can be evaluated using adrenal suppression as a sensitive surrogate for relative bioavailability to the lung after an inhalation. WHAT THIS STUDY ADDS • This study compares the relative bioavailability to the lung of inhaled fluticasone delivered via conventional pressurized metered dose inhalers (pMDI) and three antistatic spacers (plastic Zerostat‐V, plastic Aerochamber Max, and metal Nebuchamber) in patients with asthma. • All three antistatic spacers when compared with pMDI significantly increased the relative bioavailability to the lungs of inhaled fluticasone in terms of relative adrenal suppression, and there were no significant differences between the plastic and metal antistatic spacers. AIMS The systemic bioavailability of inhaled fluticasone propionate (FP) depends primarily on lung absorption and can be quantified by measuring suppression of overnight and early morning urinary cortisol/creatinine (OUCC and EMUCC, respectively). The aim of the study was to determine the relative bioavailability of hydrofluoroalkane (HFA) FP to the lungs via anti‐static plastic (Zerostat‐V and Aerochamber Max), metal (Nebuchamber) anti‐static spacers and metered dose inhaler [Flixotide Evohaler (EH) (pMDI)]. METHODS A randomized, double‐blind, double‐dummy, four‐way crossover design was used. Eighteen mild to moderate asthmatics received single doses of placebo/HFA‐FP 2 mg via the 280‐ml Zerostat‐V (ZS); 250‐ml Nebuchamber (NC); 197‐ml Aerochamber Max (AC); and pMDI (EH). Measurements of OUCC and EMUCC were made at baseline and 10 h after each dose. RESULTS Significant suppression of OUCC and EMUCC occurred from baseline with all three spacers, but not Evohaler (geometric mean fold suppression, 95% confidence interval): ZS, 2.74 (1.75, 4.30), P < 0.001; NC, 3.31 (1.81, 6.06), P < 0.001; AC, 4.98 (3.39, 7.31), P < 0.001; and for EH this was 1.42 (0.92, 2.21), P = 0.169 (equating to a 64, 70, 80 and 30% fall in OUCC via the ZS, NC, AC and EH devices, respectively). There were significant differences between all three spacers vs. EH. When compared with the Evohaler, the Zerostat V resulted in 48% greater suppression ( P = 0.009); the Nebuchamber 57% greater suppression ( P = 0.001); and the Aerochamber Max 71% greater suppression of OUCC ( P < 0.001). CONCLUSION All three antistatic spacers significantly increased the relative systemic bioavailability of HFA‐FP compared with the standard pMDI." @default.
• W2022072056 created "2016-06-24" @default.
• W2022072056 creator A5016699591 @default.
• W2022072056 creator A5027227336 @default.
• W2022072056 creator A5054519215 @default.
• W2022072056 creator A5067874881 @default.
• W2022072056 creator A5077110496 @default.
• W2022072056 date "2009-02-01" @default.
• W2022072056 modified "2023-10-17" @default.
• W2022072056 title "<i>In vivo</i>comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhaler" @default.
• W2022072056 cites W1950045808 @default.
• W2022072056 cites W2018227396 @default.
• W2022072056 cites W2032027523 @default.
• W2022072056 cites W2047633480 @default.
• W2022072056 cites W2049979738 @default.
• W2022072056 cites W2050423201 @default.
• W2022072056 cites W2054806186 @default.
• W2022072056 cites W2072635905 @default.
• W2022072056 cites W2089025869 @default.
• W2022072056 cites W2089516326 @default.
• W2022072056 cites W2091263563 @default.
• W2022072056 cites W2096165941 @default.
• W2022072056 cites W2107458483 @default.
• W2022072056 cites W2109428979 @default.
• W2022072056 cites W2110195766 @default.
• W2022072056 cites W2129210216 @default.
• W2022072056 cites W2146829659 @default.
• W2022072056 cites W2148567940 @default.
• W2022072056 cites W2150867310 @default.
• W2022072056 cites W2153308144 @default.
• W2022072056 cites W2156080652 @default.
• W2022072056 cites W2159612708 @default.
• W2022072056 cites W4241626294 @default.
• W2022072056 doi "https://doi.org/10.1111/j.1365-2125.2008.03350.x" @default.
• W2022072056 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2670376" @default.
• W2022072056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19220273" @default.
• W2022072056 hasPublicationYear "2009" @default.
• W2022072056 type Work @default.
• W2022072056 sameAs 2022072056 @default.
• W2022072056 citedByCount "21" @default.
• W2022072056 countsByYear W20220720562012 @default.
• W2022072056 countsByYear W20220720562013 @default.
• W2022072056 countsByYear W20220720562014 @default.
• W2022072056 countsByYear W20220720562016 @default.
• W2022072056 countsByYear W20220720562017 @default.
• W2022072056 countsByYear W20220720562018 @default.
• W2022072056 countsByYear W20220720562020 @default.
• W2022072056 countsByYear W20220720562023 @default.
• W2022072056 crossrefType "journal-article" @default.
• W2022072056 hasAuthorship W2022072056A5016699591 @default.
• W2022072056 hasAuthorship W2022072056A5027227336 @default.
• W2022072056 hasAuthorship W2022072056A5054519215 @default.
• W2022072056 hasAuthorship W2022072056A5067874881 @default.
• W2022072056 hasAuthorship W2022072056A5077110496 @default.
• W2022072056 hasBestOaLocation W20220720562 @default.
• W2022072056 hasConcept C126322002 @default.
• W2022072056 hasConcept C142724271 @default.
• W2022072056 hasConcept C178790620 @default.
• W2022072056 hasConcept C181389837 @default.
• W2022072056 hasConcept C185592680 @default.
• W2022072056 hasConcept C192394166 @default.
• W2022072056 hasConcept C204787440 @default.
• W2022072056 hasConcept C27081682 @default.
• W2022072056 hasConcept C2776042228 @default.
• W2022072056 hasConcept C2776954882 @default.
• W2022072056 hasConcept C2779028295 @default.
• W2022072056 hasConcept C2779227376 @default.
• W2022072056 hasConcept C2780261241 @default.
• W2022072056 hasConcept C2780667556 @default.
• W2022072056 hasConcept C2781018748 @default.
• W2022072056 hasConcept C2781212218 @default.
• W2022072056 hasConcept C42219234 @default.
• W2022072056 hasConcept C42404028 @default.
• W2022072056 hasConcept C71924100 @default.
• W2022072056 hasConcept C87813604 @default.
• W2022072056 hasConcept C98274493 @default.
• W2022072056 hasConceptScore W2022072056C126322002 @default.
• W2022072056 hasConceptScore W2022072056C142724271 @default.
• W2022072056 hasConceptScore W2022072056C178790620 @default.
• W2022072056 hasConceptScore W2022072056C181389837 @default.
• W2022072056 hasConceptScore W2022072056C185592680 @default.
• W2022072056 hasConceptScore W2022072056C192394166 @default.
• W2022072056 hasConceptScore W2022072056C204787440 @default.
• W2022072056 hasConceptScore W2022072056C27081682 @default.
• W2022072056 hasConceptScore W2022072056C2776042228 @default.
• W2022072056 hasConceptScore W2022072056C2776954882 @default.
• W2022072056 hasConceptScore W2022072056C2779028295 @default.
• W2022072056 hasConceptScore W2022072056C2779227376 @default.
• W2022072056 hasConceptScore W2022072056C2780261241 @default.
• W2022072056 hasConceptScore W2022072056C2780667556 @default.
• W2022072056 hasConceptScore W2022072056C2781018748 @default.
• W2022072056 hasConceptScore W2022072056C2781212218 @default.
• W2022072056 hasConceptScore W2022072056C42219234 @default.
• W2022072056 hasConceptScore W2022072056C42404028 @default.
• W2022072056 hasConceptScore W2022072056C71924100 @default.
• W2022072056 hasConceptScore W2022072056C87813604 @default.
• W2022072056 hasConceptScore W2022072056C98274493 @default.
• W2022072056 hasIssue "2" @default.

• next